1
|
Lichtenstein L and Hall JE: Periosteal
chondroma; a distinctive benign cartilage tumor. J Bone Joint Surg
Am. 34:691–697. 1952.
|
2
|
Buddingh EP, Naumann S, Nelson M, Neffa
JR, Birch N and Bridge JA: Cytogenetic findings in benign
cartilaginous neoplasms. Cancer Genet Cytogenet. 141:164–168. 2003.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Mandahl N, Willén H, Rydholm A, Heim S and
Mitelman F: Rearrangement of band q13 on both chromosomes 12 in a
periosteal chondroma. Genes Chromosomes Cancer. 6:121–123. 1993.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Sakai Junior N, Abe KT, Formigli LM, et
al: Cytogenetic findings in 14 benign cartilaginous neoplasms.
Cancer Genet. 204:180–186. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Damato S, Alorjani M, Bonar F, et al: IDH1
mutations are not found in cartilaginous tumours other than central
and periosteal chondrosarcomas and enchondromas. Histopathology.
60:363–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Amary MF, Bacsi K, Maggiani F, et al: IDH1
and IDH2 mutations are frequent events in central chondrosarcoma
and central and periosteal chondromas but not in other mesenchymal
tumours. J Pathol. 224:334–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Mandahl N: Methods in solid tumour
cytogeneticsHuman cytogenetics: malignancy and acquired
abnormalities. Rooney DE: Oxford University Press; New York, NY:
pp. 165–203. 2001
|
8
|
Schaffer LG, Slovak ML and Campbell LJ:
ISCN 2009: an International System for Human Cytogenetic
Nomenclature. Karger; Basel: 2009
|
9
|
Patel KP, Barkoh BA, Chen Z, et al:
Diagnostic testing for IDH1 and IDH2 variants in acute myeloid
leukemia an algorithmic approach using high-resolution melting
curve analysis. J Mol Diagn. 13:678–686. 2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Killela PJ, Reitman ZJ, Jiao Y, et al:
TERT promoter mutations occur frequently in gliomas and a subset of
tumors derived from cells with low rates of self-renewal. Proc Natl
Acad Sci USA. 110:6021–6026. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Esteller M, Hamilton SR, Burger PC, Baylin
SB and Herman JG: Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter hypermethylation
is a common event in primary human neoplasia. Cancer Res.
59:793–797. 1999.PubMed/NCBI
|
12
|
Jerónimo C, Henrique R, Oliveira J, et al:
Aberrant cellular retinol binding protein 1 (CRBP1) gene expression
and promoter methylation in prostate cancer. J Clin Pathol.
57:872–876. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Song C, Zhou X, Dong Q, et al: Regulation
of inflammatory response in human chondrocytes by lentiviral
mediated RNA interference against S100A10. Inflamm Res.
61:1219–1227. 2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Heim S and Mitelman F: Cancer
Cytogenetics: Chromosomal and Molecular Genetic Abberations of
Tumor Cells. 3rd. Wiley-Blackwell; Oxford, UK: 2009
|
15
|
Dahlén A, Mertens F, Rydholm A, et al:
Fusion, disruption, and expression of HMGA2 in bone and soft tissue
chondromas. Mod Pathol. 16:1132–1140. 2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Duncan CG, Barwick BG, Jin G, et al: A
heterozygous IDH1R132H/WT mutation induces genome-wide alterations
in DNA methylation. Genome Res. 22:2339–2355. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Turcan S, Rohle D, Goenka A, et al: IDH1
mutation is sufficient to establish the glioma hypermethylator
phenotype. Nature. 483:479–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chou AP, Chowdhury R, Li S, et al:
Identification of retinol binding protein 1 promoter
hypermethylation in isocitrate dehydrogenase 1 and 2 mutant
gliomas. J Natl Cancer Inst. 104:1458–1469. 2012. View Article : Google Scholar : PubMed/NCBI
|
19
|
Leu S, von Felten S, Frank S, et al:
IDH/MGMT-driven molecular classification of low-grade glioma is a
strong predictor for long-term survival. Neuro Oncol. 15:469–479.
2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Mellai M, Monzeglio O, Piazzi A, et al:
MGMT promoter hypermethylation and its associations with genetic
alterations in a series of 350 brain tumors. J Neurooncol.
107:617–631. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Noushmehr H, Weisenberger DJ, Diefes K, et
al: Cancer Genome Atlas Research Network: Identification of a CpG
island methylator phenotype that defines a distinct subgroup of
glioma. Cancer Cell. 17:510–522. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Koelsche C, Sahm F, Capper D, et al:
Distribution of TERT promoter mutations in pediatric and adult
tumors of the nervous system. Acta Neuropathol. 126:907–915. 2013.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Nonoguchi N, Ohta T, Oh JE, Kim YH,
Kleihues P and Ohgaki H: TERT promoter mutations in primary and
secondary glioblastomas. Acta Neuropathol. 126:931–937. 2013.
View Article : Google Scholar : PubMed/NCBI
|